1. Scrip
  2. >>Drug Pricing

‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say

 
• By Jessica Merrill

PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.

Similar
Biosimilars for Humira could experience commercial headwinds in the US • Source: Shutterstock

US market dynamics will result in headwinds for drug manufacturers hoping to make a fast return on investment from the sale of biosimilar versions of AbbVie Inc.’s blockbuster Humira (adalimumab), industry watchers said during a panel discussion on the US biosimilars market sponsored by the IQVIA Institute on 28 February.

Economic incentives for payers and the pharmacy benefit managers (PBMs) charged with negotiating formulary placement for drugs in the US are misaligned against rapid biosimilar adoption when it comes to a high-volume drug for a chronic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.